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• Bone is one of the most frequent site of metastasis in patients with
advanced cancer. Nearly all patients with myeloma, 65–75% of patients
with prostate or breast cancer, and 30–40% of patients with lung cancer
or other solid tumors, eventually develop bone metastases.
• Bisphosphonates (BPs), particularly zoledronic acid and denosumab,
were demonstrated to effectively reduce skeletal complications in
patients with bone metastases.
• However, bisphosphonate-related osteonecrosis of the jaw (BRONJ) can
occur spontaneously, favored by dental extraction, dental implant
surgery, or denture wearing, in around 6% of patients.
• In order to reduce the risk of BRONJ, a Dental Prevention Service was
created at Modena Cancer Center in 2010.
• Since 2010, all patients with bone metastases underwent a baseline
mouth assessment (dental visit, Rx orthopantomography, and eventual
tooth avulsion or dental care if necessary) prior to start BPs.
• To underline the role of dental prevention as an
effective tool to reduce the risk of BRONJ
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• BRONJ was identified with the standardized query
“osteonecrosis” among all data from patients treated at
Modena Cancer Center from 2005 to 2016.
• For each case, demographic and medical information
were analyzed, as well as data about BRONJ notification
(year of occurrence, outcome), type and duration of BP
exposure, and associated risk factors (dento-alveolar
surgery, chemotherapy, antiangiogenics).
• Data were differently analyzed taking into account the
implementation of a Dental Prevention Service in
patients candidate for BP therapy.
• Prevention of BRONJ is critical in in bone metastatic
patients.
• The incidence of BRONJ over time can drop to 1.9% when
primary and secondary prevention measures are
implemented in routine clinical practice.
• Overall, in the period 2005-2016 only 14 patients (22%)
with BRONJ received a baseline mouth assessment before
starting BP.
• All but one of them, were evaluated by Dental Prevention
Service after its foundation in 2010.
• After Dental Prevention Service institution, a drop of
BRONJ incidence from 4.1 to 1.9% was observed.
Patients’ characteristics
Median time to BRONJ 28 mos 1-89,1 mos
Mean n° of BP doses before BRONJ 25 1-90
Type of BP: 
Pamidronate->Zoledronate
Zoledronate
Zoledronate->Denosumab
Densoumab
8
51
2
2
13%
81%
3%
3%
Site: 
maxilla
mandible
15
48
24%
76%
Trigger event:
dental extraction
spontaneus
18
45
29%
71%
Concomitant medications:
none
chemo-therapy
endocrine-therapy
antiangiogenic-agents 
11
17
21
9
17%
27%
33%
14%
Treatment:
antibiotics
surgery
hyperbaric
30
29
4
48%
46%
6%
Outcome:
not yet recovered
recovered
death unrelated to BRONJ
unknown
3
13
37
10
5%
21%
59%
15%
• Among 1663 patients treated with BP, 63 cases of BRONJ 
were identified (3.8%). 
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